Susquehanna International Group’s RAPT Therapeutics RAPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-39,300
| Closed | -$1.33M | – | 13932 |
|
|
2025
Q4 | $1.33M | Buy |
+39,300
| New | +$1.22M | ﹤0.01% | 6529 |
|
|
2025
Q3 | – | Sell |
-16,600
| Closed | -$133K | – | 13633 |
|
|
2025
Q2 | $133K | Buy |
+16,600
| New | +$127K | ﹤0.01% | 11597 |
|
|
2024
Q3 | – | Sell |
-1,963
| Closed | -$47.9K | – | 12844 |
|
|
2024
Q2 | $47.9K | Buy |
1,963
+238
| +14% | +$11K | ﹤0.01% | 11431 |
|
|
2024
Q1 | $124K | Sell |
1,725
-14,450
| -89% | -$2.01M | ﹤0.01% | 11070 |
|
|
2023
Q4 | $3.22M | Buy |
16,175
+450
| +3% | +$55.7K | ﹤0.01% | 4450 |
|
|
2023
Q3 | $2.09M | Sell |
15,725
-638
| -4% | -$104K | ﹤0.01% | 5035 |
|
|
2023
Q2 | $2.45M | Sell |
16,363
-1,550
| -9% | -$241K | ﹤0.01% | 4737 |
|
|
2023
Q1 | $2.63M | Sell |
17,913
-2,725
| -13% | -$551K | ﹤0.01% | 4584 |
|
|
2022
Q4 | $3.27M | Buy |
20,638
+1,163
| +6% | +$186K | ﹤0.01% | 3876 |
|
|
2022
Q3 | $3.75M | Buy |
19,475
+11,600
| +147% | +$2.19M | ﹤0.01% | 3642 |
|
|
2022
Q2 | $1.15M | Sell |
7,875
-150
| -2% | -$20K | ﹤0.01% | 6185 |
|
|
2022
Q1 | $1.41M | Buy |
8,025
+6,150
| +328% | +$1.16M | ﹤0.01% | 6290 |
|
|
2021
Q4 | $551K | Sell |
1,875
-2,763
| -60% | -$739K | ﹤0.01% | 8921 |
|
|
2021
Q3 | $1.15M | Sell |
4,638
-1,325
| -22% | -$350K | ﹤0.01% | 7202 |
|
|
2021
Q2 | $1.52M | Sell |
5,963
-10,925
| -65% | -$2.04M | ﹤0.01% | 6613 |
|
|
2021
Q1 | $3M | Buy |
16,888
+11,563
| +217% | +$1.91M | ﹤0.01% | 4960 |
|
|
2020
Q4 | $841K | Buy |
+5,325
| New | +$1.16M | ﹤0.01% | 7111 |
|
Susquehanna International Group's RAPT Position: Q1 2026 in Review
Susquehanna International Group sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 424,862 shares — an estimated $14.4M sold.
Susquehanna International Group first reported a position in RAPT in Q1 2021 and held it in 15 quarters. The position peaked at $14.4M in Q4 2025. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.
- Susquehanna International Group reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
- Susquehanna International Group sold 424,862 RAPT Therapeutics shares in Q1 2026, an estimated $14.4M.
- Susquehanna International Group first reported a position in RAPT Therapeutics in Q1 2021 and held it in 15 quarters.
- Susquehanna International Group's RAPT Therapeutics position peaked at $14.4M in Q4 2025.
- 0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.